Yi-Zhen Liu (Yizhen Liu)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Metastatic Colorectal Cancer

Hodgkin Lymphoma

Prognostic Factors

Diffuse Large B Cell Lymphoma

Top Venues

Nature communications

Cancer medicine

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Tiantian Jing, Dianhui Wei, Xiaoli Xu, Chengsi Wu, Lili Yuan, Yiwen Huang, Yi-Zhen Liu, Yan-Yi Jiang, Boshi Wang
Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma. Nature communications 15 (1) (2024)
Guang-Liang Chen, Kai Xue, Qunling Zhang, Zu-Guang Xia, Jia Jin, Ran Li, Yi-Zhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study. Cancer medicine 13 (16) (2024)
Tiantian Jing, Dianhui Wei, Xiaoli Xu, Chengsi Wu, Lili Yuan, Yiwen Huang, Yi-Zhen Liu, Yan-Yi Jiang, Boshi Wang
Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma. Nature communications 15 (1) (2024)
Tiantian Jing, Dianhui Wei, Xiaoli Xu, Chengsi Wu, Lili Yuan, Yiwen Huang, Yi-Zhen Liu, Yan-Yi Jiang, Boshi Wang
Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma. Nature communications 15 (1) (2024)
Tiantian Jing, Dianhui Wei, Xiaoli Xu, Chengsi Wu, Lili Yuan, Yiwen Huang, Yi-Zhen Liu, Yan-Yi Jiang, Boshi Wang
Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma. Nature communications 15 (1) (2024)
Guang-Liang Chen, Kai Xue, Qunling Zhang, Zu-Guang Xia, Jia Jin, Ran Li, Yi-Zhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study. Cancer medicine 13 (16) (2024)
Yan Gao, Yi-Zhen Liu, Yafei Wang, Qingyuan Zhang, Depei Wu, Xu Ye, Jianqiu Wu, Wei Xu, Jianfeng Zhou, Yu Yang, Hong Cen, Feng Zhang, Ying Xiang, Xiaoqiong Tang, Kaiyang Ding, JinYing Lin, Lei Ma, Shunqing Wang, Hao Yu, Yang Zhao, Xijiao Liu, Fangfang Lv, Huiqiang Huang
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Cancer (2022)
Yan Gao, Yi-Zhen Liu, Yafei Wang, Qingyuan Zhang, Depei Wu, Xu Ye, Jianqiu Wu, Wei Xu, Jianfeng Zhou, Yu Yang, Hong Cen, Feng Zhang, Ying Xiang, Xiaoqiong Tang, Kaiyang Ding, JinYing Lin, Lei Ma, Shunqing Wang, Hao Yu, Yang Zhao, Xijiao Liu, Fangfang Lv, Huiqiang Huang
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Cancer 129 (4) (2022)
Yi-Zhen Liu, Liqiong Xue, Zuguang Xia, Qunling Zhang, Ye Guo
Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study. Head & neck 44 (9) (2022)
Yan Gao, Yi-Zhen Liu, Yafei Wang, Qingyuan Zhang, Depei Wu, Xu Ye, Jianqiu Wu, Wei Xu, Jianfeng Zhou, Yu Yang, Hong Cen, Feng Zhang, Ying Xiang, Xiaoqiong Tang, Kaiyang Ding, JinYing Lin, Lei Ma, Shunqing Wang, Hao Yu, Yang Zhao, Xijiao Liu, Fangfang Lv, Huiqiang Huang
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Cancer 129 (4) (2022)
Yan Gao, Yi-Zhen Liu, Yafei Wang, Qingyuan Zhang, Depei Wu, Xu Ye, Jianqiu Wu, Wei Xu, Jianfeng Zhou, Yu Yang, Hong Cen, Feng Zhang, Ying Xiang, Xiaoqiong Tang, Kaiyang Ding, JinYing Lin, Lei Ma, Shunqing Wang, Hao Yu, Yang Zhao, Xijiao Liu, Fangfang Lv, Huiqiang Huang
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Cancer 129 (4) (2022)
Yi-Zhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang, Baohua Yu, Zuguang Xia, Qunling Zhang, Dongmei Ji, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Shaoli Song, Junning Cao
Prognostic significance of clinical characteristics and 18 Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma. The Journal of international medical research 50 (1) (2022)
Yi-Zhen Liu, Kai Xue, Zuguang Xia, Jia Jin, Jiachen Wang, Hui Sun, Fangfang Lv, Xiaojian Liu, Junning Cao, Xiaonan Hong, Ye Guo, Xuejun Ma, Qunling Zhang
Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients. Cancer medicine 9 (15) (2020)
Yi-Zhen Liu, Yumei Liu, Ping Zhao, Qunling Zhang, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Junning Cao, Kai Xue
Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. Cancer management and research 12 (2020)
Yi-Zhen Liu, Pan Luo, Cheng Liu, Kai Xue, Jia Jin, Zu-Guang Xia, Xiao-Jian Liu, Qun-Ling Zhang, Jun-Ning Cao, Xiao-Nan Hong, Fang-Fang Lv
Prognostic Significance of LDH Ratio in Serum/Cerebral Spinal Fluid of Patients with Primary Testicular Diffuse Large B-Cell Lymphoma. OncoTargets and therapy 12 (2019)
Yi-Zhen Liu, Kai Xue, Bo-Shi Wang, Chun-Yan Li, Fang-Fang Lv, Jia Jin, Qun-Ling Zhang, Zu-Guang Xia, Dong-Mei Ji, Hui Sun, Jia-Chen Wang, Xiao-Jian Liu, Jun-Ning Cao, Xiao-Nan Hong
The size and depth of lesions measured by endoscopic ultrasonography are novel prognostic factors of primary gastric diffuse large B-cell lymphoma. Leukemia & lymphoma 60 (4) (2018)